Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure|
- MMP levels [ Time Frame: 16 weeks ]
|Study Start Date:||January 2004|
|Study Completion Date:||December 2005|
Drug: spironolactone + furosemide
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
No Contacts or Locations Provided